Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 3/20 | 0.35 |
| ▸ | TEC | P42680 | 2/20 | 0.35 |
| ▸ | BMX | P51813 | 2/20 | 0.35 |
| ▸ | LCK | P06239 | 2/20 | 0.34 |
| ▸ | LYN | P07948 | 1/20 | 0.34 |
| ▸ | HCK | P08631 | 1/20 | 0.34 |
| ▸ | FGR | P09769 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | FRK | P42685 | 1/20 | 0.34 |
| ▸ | BLK | P51451 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.34 |
| ▸ | ITK | Q08881 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4608626 | 0.86 | SLC2A1 (0.33) | SLC2A1EPHX2 | |
| SCHEMBL4607457 | 0.85 | SLC2A1 (0.49) | SLC2A1BTKTECBMXLCK | |
| SCHEMBL4922413 | 0.82 | SLC2A1 (0.65) | SLC2A1BTKTECBMXLCK | |
| SCHEMBL4606841 | 0.78 | LRRK2 (0.41) | BTKLCKEPHX2 | |
| Hydrochloric Acid SCHEMBL4607073 | 0.77 | TDO2 (0.34) | SLC2A1BTKTECBMXLCK | |
| SCHEMBL4607822 | 0.77 | SLC2A1 (0.37) | SLC2A1BTKTECBMXLCK | |
| SCHEMBL4607581 | 0.74 | LRRK2 (0.41) | SLC2A1SYK | |
| SCHEMBL4607056 | 0.73 | PIK3CA (0.33) | BTKTECBMXLCKSYK | |
| SCHEMBL4607554 | 0.71 | SLC2A1 (0.38) | SLC2A1SYK | |
| SCHEMBL31251374 | 0.65 | CASP1 (0.33) | BTKLCKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | GLAXO GROUP LIMITED (GB) | 2008-11-13 | — | — | US | disclosed |
| EP-1945616-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2008-07-23 | — | — | EP | disclosed |
| EP-1876895-A2 | HALOMETHYLENE ALKANONES AND FURANONES FOR USE AS BIOFILM BLOCKING SUBSTANCES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2008-01-16 | — | — | EP | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045861-A1 | CINNOLINE COMPOUNDS AS INHIBITORS OF PHOSPHODIESTERASE TYPE IV (PDE4) | GLAXO GROUP LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2006117113-A2 | HALOMETHYLENE ALKANONES AND FURANONES FOR USE AS BIOFILM BLOCKING SUBSTANCES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006032477-A1 | PULLULANASES FROM PSYCHROPHILIC ORGANISMS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005056744-A1 | HYBRID ENZYMES WITH CATIONIC BINDING DOMAINS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280911-A1 | Cinnoline Compounds as Inhibitors of Phosphodiesterase Type IV (Pde4) | PDE4A, PDE4B, PDE3B | SLC2A1 3751/4885BTK 2607/4885TEC 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.